Main navigation

Products we regulate
Product safety
How we regulate
Guidance and resources

Alphapharm Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (849)
Cancellation by sponsor (780)
Prescription medicine registration (54)
Cancellation or suspension (44)
Australian Public Assessment Report (AusPAR) (3)
Designation or determination (3)
Prescription medicine decision summary (2)
Section 14, TGO91 consent (1)

Date

2024 (18)
2023 (84)
2022 (230)
2021 (265)
2020 (113)
2019 (35)
2018 (66)
2017 (364)
2016 (34)
2015 (22)
2014 (48)
2013 (40)
2012 (61)
2011 (28)
2010 (46)
2009 (25)
2008 (10)
2007 (28)
2006 (6)
2005 (17)
2004 (15)
2003 (33)
2002 (15)
2001 (4)
2000 (14)
1999 (9)
1998 (8)
1997 (11)
1996 (10)
1995 (7)
1994 (6)
1993 (12)
1992 (11)
1991 (41)

Results for "[search-keyword]"

Search

Sponsor content

1736 result(s) found, displaying 371 to 380

ROSUVASTATIN MYLAN rosuvastatin (as calcium) 20 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

13 January 2022

Cancellation by sponsor

Requested by Alphapharm Pty Ltd
ROSUVASTATIN MYLAN rosuvastatin (as calcium) 10 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

13 January 2022

Cancellation by sponsor

Requested by Alphapharm Pty Ltd
TENOFOVIR ALPHAPHARM tenofovir disoproxil maleate 300 mg film coated tablet bottle Cancelled under Section 30(1)(c) of the Act

13 January 2022

Cancellation by sponsor

Requested by Alphapharm Pty Ltd
PACLITAXEL ALPHAPHARM paclitaxel 100 mg/16.7 mL concentrated injection vial Cancelled under Section 30(1)(c) of the Act

13 January 2022

Cancellation by sponsor

Requested by Alphapharm Pty Ltd
PACLITAXEL ALPHAPHARM paclitaxel 300 mg/50 mL concentrated injection vial Cancelled under Section 30(1)(c) of the Act

13 January 2022

Cancellation by sponsor

Requested by Alphapharm Pty Ltd
TRANDOLAPRIL ALPHAPHARM trandolapril 2mg capsules blister pack Cancelled under Section 30(1)(c) of the Act

13 January 2022

Cancellation by sponsor

Requested by Alphapharm Pty Ltd
RISDONE 6 risperidone 6 mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

13 January 2022

Cancellation by sponsor

Requested by Alphapharm Pty Ltd
RISDONE 2 risperidone 2 mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

13 January 2022

Cancellation by sponsor

Requested by Alphapharm Pty Ltd
RISDONE 4 risperidone 4 mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

13 January 2022

Cancellation by sponsor

Requested by Alphapharm Pty Ltd
RISDONE 1 risperidone 1 mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

13 January 2022

Cancellation by sponsor

Requested by Alphapharm Pty Ltd

Pages

First page
Previous page
…
Page 34
Page 35
Page 36
Page 37
Current page 38
Page 39
Page 40
Page 41
Page 42
…
Next page
Last page

Is there anything wrong with this page?

Help us improve the Therapeutic Goods Administration site

What were you doing? (mandatory)

What went wrong? (mandatory)

Leave this field blank

Using our website

Accessibility
Privacy
Disclaimer
Copyright
Freedom of information

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Subscribe to updates
Contact us
Facebook
(Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.